Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab versus placebo for early Dupuytren's disease
NL-OMON47684Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Dupuytren's contracture comparing Adalimumab with Placebo saline (2 arms). Primary endpoint: Change in hardness of selected nodule at 12 months. Started Feb 2019; status: active, not recruiting.
02
Drugs
03
Conditions
Dupuytren's contracture
Beyond the preview
Go deeper on NL-OMON47684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47684.